Revvity has announced that its Revvity Signals Software business is launching the Signals LabGistics™ solution, an AI-first scientific workflow orchestration solution designed to connect and coordinate processes, workflows and tasks from discovery to manufacturing.

Workflow design from natural-language descriptions

The solution uses AI-powered workflow design to translate natural-language descriptions and standard operating procedures into coordinated scientific workflows. Revvity said that as pharmaceutical, biotechnology and specialty chemicals organisations pursue increasingly complex innovations, from novel therapeutics to advanced material formulations, fragmented systems and manual hand-offs slow scientific progress, especially during technology transfer from R&D to manufacturing.

The company describes the product as an intelligent orchestration layer that helps organisations connect teams, systems and processes to execute workflows more seamlessly. By connecting real-time data and insights in a single digital environment, it is intended to help contextualise decision-making and continuously improve scientific processes.

“Scientific innovation is increasingly dependent on the ability to coordinate work across people, systems and stages of development,” said Kevin Willoe, president of Revvity Signals Software. “Our Signals LabGistics offering brings those moving parts together and helps organisations move promising therapies and new products forward with greater speed, consistency and confidence.”

Integration, monitoring and traceability

Revvity said the solution operates within the broader Revvity Signals Software ecosystem and is designed to work within existing laboratory and manufacturing platforms, extending to adjacent systems over time. Alongside multi-tier execution and real-time monitoring, this is intended to improve the flow of information, samples and activities across independent teams. Scientists and managers can then better understand workflow status, identify emerging bottlenecks and respond before delays affect broader development timelines.

The company said the multi-tier execution, centralised data and real-time monitoring capabilities improve visibility and traceability, and are designed to adhere to complex regulatory and quality requirements.

Compliance options and availability

The solution also offers flexible compliance and quality capabilities tailored to unique industry requirements. Revvity said these can support pharmaceutical and biotechnology organisations that need to maintain GxP compliance across connected environments, or specialty chemicals organisations and materials science companies looking to minimise additional regulatory overhead.

The Signals LabGistics solution is expected to be available in the United States, Canada, Europe and Japan in December 2026.

For more information, visit: https://shorturl.at/1QvqT
Digital issue: Please click here for more information